Abstract Hepatic stellate cells (HSCs), also known as perisinusoidal cells, are pericytes found in the perisinusoidal space of the liver. HSCs are the major cell type involved in liver fibrosis, which is the formation of scar tissue in response to liver damage. When the liver is damaged, stellate cells can shift into an activated state, characterized by proliferation, contractility and chemotaxis. The activated HSCs secrete collagen scar tissue, which can lead to cirrhosis. Recent studies have shown that in vivo activation of HSCs by fibrogenic agents can eventually lead to senescence of these cells, which would contribute to reversal of fibrosis although it may also favor the insurgence of liver cancer. HSCs in their non-active form store huge amounts of retinoic acid derivatives in lipid droplets, which are progressively depleted upon cell activation in injured liver. Retinoic acid is a metabolite of vitamin A (retinol) that mediates the functions of vitamin A, generally required for growth and development. The precise function of retinoic acid and its alterations in HSCs has yet to be elucidated, and nonetheless in various cell types retinoic acid and its receptors (RAR and RXR) are known to act synergistically with peroxisome proliferatoractivated receptor gamma (PPAR-gamma) signaling through the activity of transcriptional heterodimers. Here, we review the recent advancements in the understanding of how retinoic acid signaling modulates the fibrogenic potential of HSCs and proposes a synergistic combined action with PPAR-gamma in the reversal of liver fibrosis.
Introduction
Hepatic stellate cells (HSCs), also known as perisinusoidal cells, Ito cells or lipocytes, are non-parenchymal cells located in the space between the endothelial cells of sinusoids and the hepatocytes, representing approximately the 5-8 % of resident liver cells. As suggested by their name, HSCs show a star-like shape with the cell body lying between the parenchymal cells of the liver and a number of cytoplasmic processes embracing sinusoids and making contact with hepatocytes and with the cytoplasmic processes of other HSCs [1] [2] [3] . In the healthy liver, HSCs are found in a quiescent state and exhibit lipid droplets storing large amounts of retinoids, mainly in the form of retinyl esters [4, 5] . The term ''retinoids'' collectively refer to vitamin A (or retinol) and its metabolites [4] , which play important roles in cell proliferation, differentiation and apotosis and in organ development and homeostasis [6] . The majority of these functions are carried out by retinoic acid (RA), the main biologically active form of retinol [6, 7] . RA modulates the expression of a number of target genes through different signaling pathways requiring its binding to nuclear receptors, namely to heterodimers of nuclear retinoic acid receptors -a, -b, or -c (RARs) and retinoid X receptors -a, -b, or -c (RXRs) [6, 7] or to peroxisome proliferator-activated receptor beta (PPARb) [6] . Furthermore, RA can modulate cellular events by nongenomic signaling [6] .
Apart from the storage of retinoids, the functions of HSCs in the healthy adult liver are yet not fully understood. In recent years, new roles for HSCs in liver development during embryogenesis [1, [8] [9] [10] [11] and in immunity, as antigen-presenting cells [4, [12] [13] [14] , have been proposed. Well known instead is the pivotal role HSCs play in response to liver injury, upon which they transdifferentiate into activated cells. Activated HSCs acquire a myofibroblast-like morphology, lose their retinol stores, become proliferative and contractile, migrate to the site of injury and begin to produce extracellular matrix to protect against further damage, and cytokines and growth factors which favor the regeneration and replacement of damaged hepatocytes [8] . Chronic activation of HSCs following persistent liver damage (either due to viral hepatitis viruses, alcohol, toxins or autoimmune disorders) results in promotion of fibrosis, because of the deposition of excessive amounts of scar tissue, which alters the structure and functionality of the liver [8, 15] . Liver fibrosis often represents the starting setting for the development of cirrhosis, which may predispose to hepatocellular carcinoma (HCC).
Hepatic stellate cells' senescence as a potential mechanism of fibrosis reversal
It is known that fibrosis is a reversible process, and fibrotic tissue can be spontaneously resorbed once the injurious stimulus is over [16] . Central to fibrosis regression is programmed death of activated HSCs in response to apoptotic stimuli, which limits the number of cells performing scar tissue deposition [17, 18] . Indeed, experimental and pharmacological approaches aimed at increasing HSCs apoptosis and enhance fibrosis resolution [19] . However, aside from apoptosis, other mechanisms of activated HSCs clearance have been recognized to occur during fibrosis regression. One of these mechanisms, which has been demonstrated both in vitro and in vivo, is the reversal of activated HSCs back to quiescence [20, 21] . Cultured activated HSCs treated with adipocyte differentiation mixture or expressing ectopic pro-adipogenic transcription factors were found to get back to an inactive phenotype [21] . Similarly, in mouse models of liver fibrosis induced either with alcohol or with CCl4, Kisseleva et al. [20] found that, in the phase of recovery, a certain number of HSCs acquire an inactive phenotype which is similar to, but distinguishable from that of quiescent HSCs before activation. Furthermore, senescence is another cell fate for activated HSCs contributing to fibrosis regression [22, 23] . Cellular senescence (also called replicative senescence) is a phenomenon in which mitotic cells permanently stop dividing yet remaining metabolically active. Several events have been described as promoters of senescence, among which are telomere shortening after a number of replicative cycles [26, 27] , DNA damage [28] [29] [30] , alteration of chromatin structure [31, 32] , oncogene activation or tumorsuppressor gene loss [33] [34] [35] [36] , oxidative stress [28, [37] [38] [39] and other kinds of stress [40, 41] . Typical features that mark senescent cells are irreversible cell cycle arrest sustained by p53 and p16/Rb pathways [42] , morphological changes (above all increased cell size and flattened morphology) [43] , expression of senescence-associated bgalactosidase (SA-bgal) [44] , expression of a senescenceassociated secretory phenotype (SASP) consisting in the production of cytokines, chemokines, growth factors, proteases and other bioactive molecules acting in an autocrine and paracrine fashion [40, [45] [46] [47] . This feature is taking a center stage since the secretory pattern of senescent cells can create an inflammatory environment favoring HCC. Although long considered a mechanism to prevent proliferation of mutated cells, it is now clear that senescence may also play the opposite role, triggering tumor development and progression [45, 48, 49] .
Specifically concerning HSCs, interleukin-22 (IL-22) has been recognized as a stimulus triggering senescence [50] . IL-22 is a cytokine produced by T lymphocytes and Natural Killer (NK) cells and reported to target epithelial cells of the skin, kidney, digestive and respiratory systems and hepatocytes [51] . It acts by binding a heterodimeric receptor composed by IL-10R2 and IL-22R1, then activating the JAK/STAT and MAP kinases pathways and resulting in mediation of immune responses, tissue protection from injury and regeneration [51] . Interestingly, cultured murine and human HSCs were recently found to express the IL-10R2 and IL-22R1 receptors and, when treated with IL-22, underwent senescence [50] . Consistently, in transgenic mice overexpressing IL-22 the degree of liver fibrosis was reduced and the resolution of fibrosis was faster than in wild-type mice. This pro-senescence phenotype triggered by IL-22 occurs via the activation of the STAT3 and the SOCS3 pathways, as already shown in hepatocytes [52] , by increasing the phosphorylation levels of these effectors either in primary mouse and human HSCs or in the human LX2 HSC cell line [50] . Consistently, HSCs lacking STAT3 or SOCS3 fail to induce p53 and p21, which are likely responsible for the cell cycle block occurring during senescence [50] .
Another inducer of senescence in HSCs is represented by CCN1 (also known as CYR61 or cysteine-rich 61) [53] , a non-structural protein of the extracellular matrix whose expression is induced upon injury [22, 53] . Mice lacking hepatic CCN1 treated with the hepatotoxic compound carbon tetrachloride (CCl 4 ) exhibit a more pronounced liver fibrosis and a decreased number of senescent cells, as judged on the basis of the expression of the SA-b-Gal marker, when compared to control mice [53] . Moreover, purified CCN1 administered to isolated activated HSCs pushes them into senescence by binding to a 1 b 1 integrin, inducing the Rac1/Nox1 pathway, and resulting in accumulation of reactive oxygen species (ROS) [53] , which are known mediators of senescence [54] [55] [56] .
On the other hand, the commitment of HSCs toward senescence is counteracted by adenosine, a molecule rapidly produced in response to cell injury [24] . Binding of adenosine to its A 2A receptor on HSCs has a pro-fibrotic effect since it stimulates collagen production [57] . Ahsan et al. [24] demonstrated that, by binding to the A 2A receptor on both LX2 cell line and primary rat HSCs, adenosine activates the PKA/Rac1/p38MAPK pathway and this results in suppression of p53 and Rb, two proteins required for senescence initiation.
Based on the mechanisms described above, it is clear that once activated the fate of HSCs (proliferation, apoptosis, inactivation or senescence) depends on an ill-known balance between pro-and anti-fibrotic endogenous molecules acting locally.
Retinol metabolism and retinoic acid signaling in hepatic stellate cells
A hallmark of HSCs in their quiescent state in healthy liver is the storage of large amounts of vitamin A (or retinol) in the form of lipid droplets of retinyl esters, mostly retinylpalmitate [4, 5] .
Vitamin A and its metabolites, collectively known as retinoids, are essential for normal cell growth and differentiation, for vision, reproduction and for the proper functioning of the immune system [4, 5, 7] . The source of retinoids is represented by animal and plant foods, the latter mainly containing carotenoids, which then need to be converted into retinoids [58] . Once absorbed by the intestine, retinoids bound to chylomicrons enter the circulation and are targeted to liver and other organs and tissues, where retinol is converted into retinaldehyde and this, in turn, is oxidized to retinoic acid (RA) [6] . RA is the main biologically active form carrying out the majority of the aforementioned functions [6, 7] , especially in its all-trans and 9-cis isomeric forms [4] . Canonically, RA acts by binding to nuclear retinoic acid receptor -a, -b, or -c (RARs) working as heterodimer with retinoid X receptor -a, -b, or -c (RXRs) [59] and resulting in regulating the expression of hundreds of target genes containing a retinoic acid responsive element (RARE) [6, 7] . In addition to this signaling pathway, however, RA is known to also bind another kind of nuclear receptor, namely peroxisome proliferator-activated receptor beta (PPARb), and even to exert its effects in a non-transcriptional way, by activating kinase cascades rather than gene expression [6, 7] .
The liver is the main organ involved in retinoid storage and metabolism. In particular, hepatocytes take up retinoids from the bloodstream, hydrolyze retinyl esters, conjugate the hydrophobic retinol with a retinol binding protein (RBP) and transfer the complex retinol-RBP to HSCs, in which it is again esterified and stored in lipid droplets. HSCs account for the storage of up to 80 % of the total body retinol content [4] and are responsible for its release into the bloodstream when the dietary intake does not meet the body requirement [5, 60] . HSCs not only store retinol, but also express enzymes for its metabolism to retinaldehyde and enzymes for the conversion of retinaldehyde to RA [5, 61, 62] . HSCs express both RARs and RXRs and are therefore able to respond to RA by modulating target genes expression [5, [62] [63] [64] [65] (Fig. 1) .
Following liver injury, HSCs undergo a process of activation during which they become myofibroblast-like, proliferative and fibrogenic. The activation of HSCs is accompanied by a marked depletion of retinoid stocks [5, 60] , even though the meaning of this event is still not fully understood. Whether retinol loss is a cause or a secondary effect of HSCs activation or whether the administration of retinol/RA could have a therapeutic effect in liver disease is not clear [60, 66] . A number of reports would suggest a potential use of retinol/RA as anti-fibrotic drug (see Table 1 ). Studies on cultured cells showed retinoids to inhibit HSCs proliferation and activation [67] [68] [69] [70] [71] . In vivo studies demonstrated that the administration of retinol or its derivatives decreases liver fibrosis in different experimental models [72] [73] [74] [75] [76] [77] . Beta carotene, a precursor of retinol, was shown to cause a milder pathological phenotype in a rat model of CCl 4 -induced hepatic fibrosis when compared to untreated controls, without any toxic effect [75] . Consistently, retinol administration prevented liver fibrosis induced by CCl 4 by suppressing HSCs activation [73, 76] . Retinylpalmitate administration (overall 2, 10 or 20 9 10 4 UI/ rat) 2 weeks before rats were injured with a single injection of dimethylnitrosamine or for the last 2 weeks in rats injured with pig serum for 10 weeks decreased the number of activated HSCs, thereby preventing collagen deposition and fibrosis in liver [72] . The administration of low doses (150 lg/kg body weight) of all-trans RA isomer for 4 weeks was found to alleviate ethanol-induced liver damage in rats [74] , and accordingly, this was confirmed in a study by Hisamori, in which 0.5 mg/mouse of all-trans RA three times per week was found to ameliorate CCl4-induced liver fibrosis in mice [77] . On the other hand, few conflicting papers exist reporting a hepato-toxic and pro-fibrotic effect of retinoids (see Table 1 ) [78] [79] [80] . Toxicity of retinoids, however, would seem to be dosedependent. This was observed both in an animal model of CCl 4 -induced liver fibrosis, where rats fed a high-vitamin A diet showed a more pronounced fibrosis and a higher mortality than rats fed a standard diet [80] , and in humans, where the higher intake of vitamin A was associated with the worst clinical manifestations of the liver disease, while lower intake was associated with milder phenotypes [78] . Consistently, the pro-fibrotic action of 9-cis-RA found by Okuno et al. [79] was observed at relatively Fig. 1 HSCs are able to metabolize retinol to give both retinyl esters (then stored in lipid droplets) and retinoic acid. Moreover, HSCs express the nuclear receptors for retinoic acid RARs, which, together with RXRs, bind to DNA on Retinoic Acid Responsive Elements (RARE) and modulate target genes expression All-trans retinoic acid Rat Amelioration of eth a no I-induced liver injury Pan et al. [74] Beta carotene Rat Alleviation of CCl 4 -induced hepatic inflammation and fibrosis Seifert et al. [75] Vitamin A Rat Suppression of hepatic fibrosis induced by CCL 4 /pig serum Senoo and Wake [76] All-trans retinoic acid Mouse Amelioration of CCl 4 -induced liver fibrosis Hisamori et al. [77] Pro-fibrotic effect of retinoids 9-cis-retinoic acid Rat Exacerbation of pig serum-induced liver fibrosis Okuno et al. [79] Vitamin A (high levels)
Rat Exacerbation of CCl 4 -induced liver fibrosis Vollmar et al. [80] Vitamin A Humans Dose-dependent chronic liver damage Geubel et al. [78] higher dosage (40 mg/kg, 5 times per week) compared to other aforementioned studies. From a practical point of view, several methods exist to detect HSCs depletion and the consequent regression of fibrosis. In experimental models, HSCs can be detected by staining with gold chloride which accumulates into lipid droplets [81] , by fluorescence microscopy which exploits the vitamin A-specific autofluorescence [82] or by immunohistochemical detection of HSCs activation markers, namely desmin [83] , a-smooth muscle actin (a-SMA) [73, 84] and Glial Fibrillary Acidic Protein (GFAP) [85] . In the clinical field, instead, liver biopsy has been for long time the gold standard for assessing and monitoring liver fibrosis in patients. Nevertheless, some disadvantageous aspects of this tool, such as invasiveness, expensiveness and possible unrepresentativeness of the sampled tissue, have raised the need to develop alternative or additional methods to measure liver fibrosis [86] . Among these, transient elastography (Fibroscan) is a technology that converts the velocity of an ultrasound wave passing through the liver into a measure of liver stiffness [87] . Moreover, radiological (such as magnetic resonance elastography) and different serological tests (measuring both direct and indirect serum markers of liver fibrosis) have been proposed to diagnose and monitor fibrosis progression/regression (see [86] for extensive review).
Another controversy concerns the responsiveness of HSCs to retinoids in their activated state [63] . As already stated, quiescent HSCs express the nuclear receptors RARs and RXRs through which they modulate gene expression upon RA stimulus [5] . The expression of these receptors, on the contrary, was found to be down-regulated at the mRNA level and undetectable at the protein level in activated HSCs and not to increase upon exogenous RA administration [64, 65] , thus suggesting HSCs unresponsiveness to RA during activation. Opposing evidence is provided by Mezaki et al. [63] who showed the protein expression of the receptors RAR-a and RAR-b to be increased in activated rat HSCs, despite lower mRNA levels. Moreover, HSCs were found to become responsive to all-trans RA only during activation due to post-transcriptional up-regulation of RAR-a.
Other lines of evidence support the importance of HSCs and retinol metabolism in liver health. RA plays a role in the negative modulation of liver fibrosis through the activation of the immune system cells, and namely NK cells. Early activated HSCs express high levels of retinoic acid early inducible gene 1 (RAE-1) which binds the NKG2D receptor on NK cells resulting in their activation [52] . Activated NK cells, in turn, become cytotoxic toward activated HSCs and HSC killing ameliorates fibrosis [5, 52, 88] .
Finally, the patatin-like phospholipase domain-containing 3 (PNPLA3) has been identified as a lipase catalyzing the hydrolysis of retinyl esters in HSCs [89] that would account for the retinol stores depletion occurring during cell activation. Interestingly, the I148 M polymorphism in PNPLA3 gene in HSCs, causing loss of retinylesterase activity, is associated with chronic liver disease and hepatocellular carcinoma [89, 90] .
Retinoic acid and senescence
As stated above, HSC senescence could represent a mechanism of fibrosis reversal [23] [24] [25] . Retinoids have their clinical application in the therapy of some kinds of hematological [91] [92] [93] and solid cancers [94] [95] [96] [97] and in the prevention of pre-neoplastic to neoplastic disease progression [95, 96, 98] . The rationale for this use relies on at least three mechanisms of action: promotion of differentiation of abnormal cells back to normal, induction of apoptosis, block of cell cycle at the G 1 stage [99] . As for the cell cycle arrest, all-trans RA was found to repress positive G 1 regulators and to up-regulate the expression of cycle inhibitors, such as p16, p21 and p27 [99] . Since p16 and p21 are involved in the process of senescence, Park et al. [99] investigated on whether all-trans RA could promote senescence as well. They found it to cause irreversible cell cycle arrest at G 1 phase in the human hepatic cell lines HepG2 and Hep3B, in the human embryonic kidney cell line HEK293 and in the human breast cancer cell line MCF-7. This arrest was in every case dependent on the up-regulation of p16 and/or p21 [99] . Similarly, retinoids were found to induce senescence in T cell leukemia cells [100] .
An interesting evidence linking RA with senescence in stellate cells was obtained by Froeling et al. [101] in pancreatic stellate cells (PSCs), a kind of cells located in the periacinar, perivascular and periductal regions of the exocrine pancreas, and sharing many morphological and functional features with HSCs [102] . As their liver counterpart, indeed, PSCs in their quiescent state store retinolrich lipid droplets, which are depleted upon cell activation [103] . Once activated, PSCs become myofibroblast-like, motile and proliferative and produce huge amounts of extracellular matrix components driving the fibrogenic process [103] . Interestingly, all-trans RA administration was shown to restore a quiescent state in PSCs, both in vitro and in vivo, thus slowing pancreatic cancer progression [101] .
Although until now no reports are available about a putative ability of retinoids to induce senescence in HSCs, one might speculate that retinoid treatment could potentially activate the senescence program in these cells too, and this would contribute to reverse HSCs activation and thus to reverse liver fibrosis.
Potential cross talk between retinoic acid and PPAR-gamma signaling
As discussed above, the canonical signaling of RA is through its receptors RARs and RXRs, the latter being prone to form heterodimers with other nuclear receptors, among which PPARs [104, 105] .
PPARs are a family of nuclear ligand-activated transcription factors regulating metabolism, above all the lipid one, in inflammation, cell growth and differentiation [106] [107] [108] . This family includes three members, namely PPARa, PPARb/d and PPARc, differing from each other for tissue distribution, ligand selectivity and biochemical properties [106] . The PPARs work as heterodimers with RXRs, and they are activated upon binding of either natural or synthetic lipidic compounds, which induce structural changes making the PPAR-RXR complex able to bind to specific responsive sequences on DNA and to allow target gene expression [107, 108] . PPARc is the most studied among PPARs. It exists in two splicing-generated isoforms, PPARc1 and PPARc2 [109] , the former being ubiquitously expressed, while the latter nearly restricted to adipose tissue [106] . PPARc is mainly known for its central role in driving adipogenesis and lipid metabolism, since it promotes the expression of genes involved in lipid uptake and storage [107] . Moreover, PPARc regulates adipose secretions such as adiponectin, leptin, resistin, TNF-a [110] [111] [112] and it takes part in glucose homeostasis and response to insulin [106, 113, 114] , as it upregulates the glucose transporter 4 (GLUT4) [115] (Fig. 2) . The latter aspect has a considerable importance in the clinical field, where a class of drugs known as thiazolidinediones (TZD), used as insulin sensitizers in the treatment of type 2 diabetes, have revealed to be PPARc activators [116] [117] [118] .
Unlike PPARa and PPARb/d, PPARc is poorly expressed in the liver [119] , and nevertheless it is essential for lipid metabolism in this organ. Studies performed in liver-specific knock-out mouse models demonstrated that liver ablation of PPARc impairs triglyceride clearance, increases body fat mass [120] , decreases the expression of genes involved in lipogenesis, lipid transport and b-oxidation and protects from the development of hepatic steatosis [120, 121] . Moreover, PPARc has a protective role against liver fibrosis, since in vivo fibrogenesis upon injury turned out to be decreased in PPARc-depleted and enhanced in PPARc-overexpressing rat livers [122, 123] . This modulation of liver fibrosis by PPARc is likely due to its effect on HSCs, since PPARc agonists, ectopic expression of PPARc or treatment with the adipocyte differentiation mix (IBMX, dexamethasone and insulin) in activated HSCs, were shown to inhibit proliferation, induce apoptosis and cell cycle arrest and promote reversal from an activated to a quiescent state [21, [124] [125] [126] [127] . Similarly, also in pancreatic stellate cells PPARc agonists or PPARc ectopic expression was shown to induce a quiescent phenotype [128] . PPARc expression in HSCs is regulated epigenetically, requiring the intervention of three actors, namely miR132, the methyl-CpG binding protein 2 (MeCP2) end the histone methyltransferase EZH2. In detail, down-regulation of miR132 releases the translational block on MeCP2, which is recruited to the PPARc promoter where it directly methylates H3K9 and causes H3K27 methylation by EZH2. Promoter methylation results in PPARc repression, which is essential for HSCs transdifferentiation into myofibroblasts [129] .
Whether PPARc effects on HSCs are somehow related to retinol metabolism in these cells is still uncertain, although they share the same trend: as retinol, also PPARc is abundant in quiescent HSCs and dramatically decreases upon activation [127, 130] . Furthermore, several analogies subsist between HSCs and adipocytes: both cell types store lipid droplets, and both undergo a process of differentiation/transdifferentiation in which PPARc is a master regulator. Both preadipocytes and activated HSCs have a fibroblast-like shape and express the same types of interstitial collagens. Because of all these similarities, it is currently believed that these cell types are strongly interrelated and maybe regulated by the same master transcription factor, namely PPARc [21, 131] .
Some reports support the existence of a combined and synergistic action of RA and PPARc in HSC fate and, thus, in the course of liver fibrosis [132, 133] . Combined treatment with the PPARc ligand 15-D12,13-prostaglandin L (2) and the RXR ligands all-trans RA and 9-cis-RA on rat primary HSCs led to cell cycle arrest, inhibition of lipid droplets release and down-regulation of fibrotic markers Fig. 3 such as collagen Ia1 and aSMA to an extent which is greater than the effect produced by each ligand alone [133] . The reciprocal interconnection between PPARc and retinoids, however, is quite controversial. The all-trans RA was found to protect mice from diet-induced hepatic steatosis through a cascade culminating in the suppression of the lipogenic PPARc2: All-trans RA binding to RAR activates the repressor hairy and enhancer of split 6 (Hes6) which, in turn, represses PPARc2 expression [134] . Moreover, RA and the synthetic retinoid fenretinide block the C/EBPa-PPARc pathway in the adipogenic process [135] [136] [137] and, accordingly, the RARa antagonist Ro 41-5253 promotes pre-adipocytes differentiation into mature adipocytes by working as activator of PPARc [138] .
Discordantly, in myeloid cells retinoids were reported to enhance PPARc expression and activity, which is required for the differentiation of this lineage [139] . This would suggest that the cross talk between retinoids and PPARc is cell type-specific.
Much less information is available for the inverse relationship between retinoids and PPARc, i.e., whether PPARc can modulate retinoid metabolism. In human dendritic cells, PPARc activation induces the expression of genes responsible for retinol metabolism and conversion to all-trans RA, which is at last able to modulate immune cell functions [140] .
In light of all these observations, and considered that it is expressed in quiescent and repressed in activated HSCs, PPARc has been proposed to potentially represent a new molecular target in the reversal of liver fibrosis [130, 131] .
Conclusion
Liver fibrosis is a scarring process taking place as a consequence of chronic damage and inflammation of this organ and represents a major clinical challenge since it degenerates into cirrhosis with consequent liver failure and poor prognosis. The main responsible cells for fibrogenesis are HSCs which, upon liver injury, undergo an activation process and begin to produce and deposit extracellular matrix forming scar tissue.
Fibrosis has long been considered an irreversible mechanism, but recently it has been uncovered that HSCs may undergo a phenotype reversion accounting for fibrosis regression [25] .
The hallmark of HSCs is the storage of large amounts of retinol in the form of retinyl esters in lipid droplets which are depleted upon cell activation, generating metabolically active forms of RA [5, 60] . Concomitantly, PPARc expression, which is substantial in quiescent HSCs, significantly decreases the following activation [122, 123] . Since RA acts through retinoid receptors which synergize with PPARc and since both retinoids and PPARc have proven to be able to reverse HSCs activation and liver fibrosis [132, 133] , it is tempting to propose that a combined treatment with retinoid receptor agonists and PPARc agonists may potentially represent a new and more beneficial strategy in the clinical management of liver fibrosis (Fig. 3) .
